Risperidone - ValiSeek/Ambrose Healthcare
Alternative Names: VAL-401Latest Information Update: 21 Aug 2025
At a glance
- Originator Tangent Reprofiling
- Developer Valiseek
- Class Antidepressants; Antineoplastics; Antipsychotics; Behavioural disorder therapies; Fluorinated hydrocarbons; Isoxazoles; Mood stabilisers; Piperidines; Pyrimidinones; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Adenocarcinoma
- Discontinued Non-small cell lung cancer
Most Recent Events
- 20 Jun 2025 Ambrose Healthcare announces intention to submit regulatory application
- 20 Jun 2025 Ambrose Healthcare plans clinical trials
- 18 Jun 2024 Discontinued - Phase-II for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Georgia (PO) (ValiRx website, June 2024)